<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34128759</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Use of M-M-R II outside of the routinely recommended age range - a systematic literature review.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>7</EndPage>
          <MedlinePgn>1-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.1933874</ELocationID>
        <Abstract>
          <AbstractText>M-M-R®<sub>II</sub> (M-M-R II) is routinely used in many countries at 12-15 months with a second dose at 4 to 6 years of age. However, the vaccine may need to be administered at other ages due to delays in the immunization schedule or in certain situations such as outbreaks or international travel. A systematic literature review was conducted to evaluate efficacy, immunogenicity and safety of M-M-R II among 6- to 11-month-olds and persons ≥7 years of age. A search for randomized controlled trials (RCTs) was conducted in 2019 including Medline, Embase and Cochrane CENTRAL. Only one study reported seroconversion rates after one dose in infants at 9 months of age: 87.4% (measles), 92.3% (mumps), and 91.2% (rubella); no safety data were reported. Seven studies reported immunogenicity and safety data for M-M-R II at ≥7 years of age. Seroconversion rates ranged from 96%-100% (measles), 65%-100% (mumps), and 91%-100% (rubella). Rates of selected adverse events ranged from 5.2%-8.7% for fever (≥38°C or ≥38.1°C), 2%-33.3% for injection site reactions, and 0.4% for measles/rubella-like rash (one study). No efficacy studies were found. This literature review identified RCTs with evidence to support that M-M-R II is immunogenic and well tolerated in individuals ≥7 years of age.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pawaskar</LastName>
            <ForeName>Manjiri</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmidt</LastName>
            <ForeName>Elvira</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0001-6159-4787</Identifier>
            <AffiliationInfo>
              <Affiliation>Certara Germany GmbH (Formerly Analytica Laser), Loerrach, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marshall</LastName>
            <ForeName>Gary S</ForeName>
            <Initials>GS</Initials>
            <Identifier Source="ORCID">0000-0002-8731-6926</Identifier>
            <AffiliationInfo>
              <Affiliation>Norton Children's and University of Louisville School of Medicine, Louisville, KY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fergie</LastName>
            <ForeName>Jaime</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-1111-0892</Identifier>
            <AffiliationInfo>
              <Affiliation>Texas A&amp;M University College of Medicine, Driscoll Children's Hospital, Corpus Christi, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Richardson</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saldutti</LastName>
            <ForeName>Louise Parks</ForeName>
            <Initials>LP</Initials>
            <AffiliationInfo>
              <Affiliation>Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Se</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Former Employee of Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neumann</LastName>
            <ForeName>Monika</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-8052-5429</Identifier>
            <AffiliationInfo>
              <Affiliation>Certara Germany GmbH (Formerly Analytica Laser), Loerrach, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koller</LastName>
            <ForeName>Linnea</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-1674-4007</Identifier>
            <AffiliationInfo>
              <Affiliation>Certara Germany GmbH (Formerly Analytica Laser), Loerrach, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuter</LastName>
            <ForeName>Barbara</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Former Employee of Merck &amp; Co., Inc., Kenilworth, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D022542">Measles-Mumps-Rubella Vaccine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008457" MajorTopicYN="Y">Measles</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022542" MajorTopicYN="N">Measles-Mumps-Rubella Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009107" MajorTopicYN="Y">Mumps</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012409" MajorTopicYN="Y">Rubella</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">MMR vaccine</Keyword>
        <Keyword MajorTopicYN="Y">age</Keyword>
        <Keyword MajorTopicYN="Y">efficacy</Keyword>
        <Keyword MajorTopicYN="Y">immunogenicity</Keyword>
        <Keyword MajorTopicYN="Y">infants</Keyword>
        <Keyword MajorTopicYN="Y">measles</Keyword>
        <Keyword MajorTopicYN="Y">mumps</Keyword>
        <Keyword MajorTopicYN="Y">rubella</Keyword>
        <Keyword MajorTopicYN="Y">safety</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>13</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34128759</ArticleId>
        <ArticleId IdType="pmc">PMC8920138</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.1933874</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC) . Complications of measles. [Internet]; 2020. 
[accessed 2020 October
30]. https://www.cdc.gov/measles/symptoms/complications.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC) . Epidemiology and prevention of vaccine-preventable diseases. Appendix E: data and statistics. Impact of Vaccines in the 20th and 21st Centuries; 2020 [accessed 2020 Nov 17]. https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/e/impact.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC) . Measles cases and outbreaks. [Internet]; 2020. 
[accessed 2020 October
30]. https://www.cdc.gov/measles/cases-outbreaks.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC) . Rubella in the U.S. [Internet]; 2020. 
[accessed 2020 Nov
17]. https://www.cdc.gov/rubella/about/in-the-us.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC) . Mumps cases and outbreaks. [Internet]; 2020. 
[accessed 2020 Nov
17]. https://www.cdc.gov/mumps/outbreaks.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Marin M, Broder KR, Temte JL, Snider DE, Seward JF.. 
Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010. 
May
7;59(RR–3):1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20448530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Centre for Disease Prevention and Control (ECDC) . ECDC vaccine scheduler: recommended vaccinations: measles, Mumps, Rubella [Internet]. [accessed 2020 Dec
14]. https://vaccine–schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&amp;SelectedCountryIdByDisease=−1;https://vaccine–schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=9&amp;SelectedCountryIdByDisease=−1;https://vaccine–schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=10&amp;SelectedCountryIdByDisease=−1.</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC) . Measles, mumps, and rubella (MMR) vaccination: what everyone should know [Internet]. [accessed 2020 December
14]. https://www.cdc.gov/vaccines/vpd/mmr/public/index.html.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization (WHO) . Measles vaccines: WHO position paper - April 2017. Wkly Epidemiol Rec
[Internet]. 2017. 
Apr
28;92(17):205–27. http://apps.who.int/iris/bitstream/10665/255149/1/WER9217.pdf?ua=1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28459148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zucker JR, Rosen JB, Iwamoto M, Arciuolo RJ, Langdon-Embry M, Vora NM, Rakeman JL, Isaac BM, Jean A, Asfaw M, et al. Consequences of undervaccination — measles outbreak, New York City, 2018–2019. N Engl J Med. 2020;382(11):1009–17. doi:10.1056/NEJMoa1912514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1912514</ArticleId>
            <ArticleId IdType="pubmed">32160662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuehn BM. Drop in vaccination causes surge in global measles cases, deaths. Jama. 2021. 
Jan
19;325(3):213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33464348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). [Internet]; 2020. 
www.training.cochrane.org/handbook.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31643080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis. 2004. 
May
01;189(SUPPL. 1):S116–S22. doi:10.1086/378691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/378691</ArticleId>
            <ArticleId IdType="pubmed">15106100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos BA, Stralioto SM, Siqueira MM, Ranieri TS, Bercini M, Schermann MT, Wagner MB, Silveira TR. Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996. Revista Panamericana De Salud Publica/Pan Am J Public Health. 2006Nov;20(5), 299–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17316487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martinez D, Trumbo SP, Fernandez de Castro J. Antibody persistence in children aged 6-7 years one year following booster immunization with two MMR vaccines applied by aerosol or by injection. Vaccine. 2017. 
May
25;35(23):3116–22. doi:10.1016/j.vaccine.2017.04.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.04.027</ArticleId>
            <ArticleId IdType="pubmed">28457672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Ortega JL, Bennett JV, Castaneda D, Martinez D, Fernandez de Castro J. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route. Vaccine. 2010. 
Oct
18;28(44):7228–32. doi:10.1016/j.vaccine.2010.08.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.08.055</ArticleId>
            <ArticleId IdType="pubmed">20800111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarno MJ, Blase E, Galindo N, Ramirez R, Schirmer CL, Trujillo-Juarez DF. Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection. Pediatr Infect Dis J. 2000;19(9):839–42. doi:10.1097/00006454-200009000-00006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00006454-200009000-00006</ArticleId>
            <ArticleId IdType="pubmed">11001106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gothefors L, Bergstrom E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis. 2001;33(7):545–49. doi:10.1080/00365540110026593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00365540110026593</ArticleId>
            <ArticleId IdType="pubmed">11515768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassidy WM, Jones G, Williams K, Deforest A, Forghani B, Virella G, Venters C. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health. 2005. 
Mar;36(3):187–92. doi:10.1016/j.jadohealth.2004.02.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jadohealth.2004.02.021</ArticleId>
            <ArticleId IdType="pubmed">15737773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: a phase III, randomized study. Hum Vaccin Immunother. 2018. 
Nov
02;14(11):2624–31. doi:10.1080/21645515.2018.1489186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2018.1489186</ArticleId>
            <ArticleId IdType="pmc">PMC6314414</ArticleId>
            <ArticleId IdType="pubmed">29902133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos BA, Ranieri TS, Bercini M, Schermann MT, Famer S, Mohrdieck R, Maraskin T, Wagner MB. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Revista Panamericana De Salud Publica/Pan Am J Public Health. 2002. 
Oct
01;12(4):240–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12431355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marin M, Marlow M, Moore KL, Patel M. Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. Mmwr. Morbidity Mortality Weekly Rep. 2018. 
Jan
12;67(1):33–38. doi:10.15585/mmwr.mm6701a7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15585/mmwr.mm6701a7</ArticleId>
            <ArticleId IdType="pmc">PMC5769794</ArticleId>
            <ArticleId IdType="pubmed">29324728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011. 
Oct;18(343):d5928. doi:10.1136/bmj.d5928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId>
            <ArticleId IdType="pmc">PMC3196245</ArticleId>
            <ArticleId IdType="pubmed">22008217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grey Literature International Steering Committee (GLISC) . Guidelines for the production of scientific and technical reports: how to write and distribute grey literature, Version 1.0. 2006; [accessed 2019 Sep
12]. http://eprints.rclis.org/7469/1/nancy.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Farace DJ, Schöpfel J. Introduction grey literature. 0.1 definitions. Grey literature in library and information studies. Berlin; New York: De Gruyter Saur; 2010. 1. https://library.oapen.org/handle/20.500.12657/45661?show=full</Citation>
        </Reference>
        <Reference>
          <Citation>Schöpfel J.
Towards a Prague definition of grey literature. at: twelfth international conference on grey literature: transparency in grey literature grey tech approaches to high tech issues; 2010 Dec
6-7; Prague (Czech Republic). 2019. https://archivesic.ccsd.cnrs.fr/sic_00581570.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
